Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Author's Avatar
Feb 25, 2021
Article's Main Image

Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX'

Cash and cash equivalents of over $120 million as of merger close

Registration trial for the treatment of relapsed/refractory EBV-positive lymphoma expected to begin in 1H2021

PR Newswire